Ocugen Inc., a leader in gene therapies for blindness diseases, has entered a partnership with a prominent pharmaceutical and healthcare company in Korea. This collaboration grants the Korean company exclusive rights to Ocugen's OCU400, an innovative modifier gene therapy for retinitis pigmentosa. The agreement includes significant financial terms, with Ocugen set to receive up to $11 million from upfront and development milestone payments. Furthermore, Ocugen will earn sales milestones and a 25% royalty on net sales. The company will also handle the commercial supply of OCU400. This partnership aims to leverage the Korean company's expertise to treat thousands of patients with retinitis pigmentosa in Korea, aligning with Ocugen's strategy to maximize patient reach and shareholder returns.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.